2020年6月9日

英国剑桥合成生物学启动生物——以前Elpis生物医学——已经筹集了4150万美元增长资本支持的标志性的美国生命科学投资者。这是剑桥大学消磨一个耸人听闻的结果由马克·科特博士和将加速生物过渡到工程公司的目标。我们打里克Klausner,鲍勃·尼尔森和吉姆Tananbaum与一些生物发现了生命的“操作系统”,加快公司对所有人类细胞的工业规模生产的驱动。生物,剑桥大学合成生物学公司剥离出来,2016年数据科学与生物学结合代码细胞人类的福祉。运输带来的系列其总资金5000万美元。强烈声明支持技术的投资是由三个生命科学世界顶级投资者和企业家。理查德·克劳斯纳是前美国国家癌症研究所的创始人和主任莱尔Immunopharma,朱诺和圣杯。吉姆Tananbaum Foresite资本的创始人兼首席执行官,目前医疗投资公司管理的资产约30亿美元。罗伯特•尼尔森是拱Venture Partners的联合创始人兼董事总经理。他加入拱在成立初期发挥了重要作用采购、融资和发展的100多家公司,包括27已达到估值超过10亿美元。 German company Blueyard Capital also invested. Bit Bio’s aim is to decode ‘cellular identity’ in order to generate every cell type of the human body. Its platform technology, opti-ox, enables precise reprogramming of stem cells and induces them to take on a new identity. They become specialised cells, such as those in the liver, brain or immune system. As a result, the company is already able to produce human cells at unmatched scale, speed and consistency. Founder and CEO Dr Mark Kotter, who developed opti-ox in his lab at Cambridge University, said: “Our moonshot goal is to develop a platform capable of producing every human cell type. “This is possible once we understand the genes governing human cell behaviour, which ultimately form the ‘operating system of life’. This will unlock a new generation of cell and tissue therapies for tackling cancer, neurodegenerative disorders and autoimmune diseases and accelerate the development of effective drugs for a range of conditions. “The support of leading deep tech and biotech investors will catalyse this unique convergence of biology and engineering.” Lead investor and Bit Bio adviser Rick Klausner said: “Bit Bio is based on beautiful science. The company’s technology has the potential to bring the long-awaited precision and reliability of engineering to the application of stem cells. “Bit Bio’s approach represents a paradigm shift in biology that will enable a new generation of cell therapies, improving the lives of millions.” The investors are supporting the company so it can continue to develop its underlying scientific principles. The injection of funding will enable Bit Bio to grow the talent and operations it needs to realise its ambitions. The development of new cancer-defeating cell therapies is currently obstructed by the scarcity of human cells. As a result, cell therapies remain expensive and difficult to scale. Furthermore, consistent access to functional human cells will unlock the potential of cell therapies and improve the efficiency of drug development. Moreover, at present less than 3% of new drugs make it to the clinical stage. This is in part caused by differences between the animal models and cell lines used for drug development and human biology. The supply of human cells resulting from Bit Bio’s approach aims to tackle this problem. At the same time, the company’s technology will reduce the need for animal studies, alleviating unnecessary animal suffering. Bit Bio has assembled a deep base of scientific support. Its team includes chief scientific adviser Dr Roger Pedersen, one of the pioneers of human stem cell biology, scientific adviser Dr Marius Wernig, a pioneer in cell reprogramming and co-director of the Stanford Stem Cell Institute, scientific adviser Dr John Connolly, a leading translational immunologist with years of experience in cell therapy, and scientific adviser Dr Ramy Ibrahim, a leader in clinical immuno-oncology. Related Articles